DCLLSG

Publikationen

  1. 2017
  2. 2016
  3. 2015
  4. 2014
  5. 2013
  6. 2012
  7. 2011
  8. 2010
  9. 2009
  10. 2008
  11. 2007
  12. 2006
  13. 2005
  14. 2004
  15. 2003
  16. 2002
  17. 2001
  18. 2000
  19. 1999
  20. 1997
  21. 1996

 

2017

Steinbrecher D, Jebaraj BMC, Schneider C, Edelmann J, Cymbalista F, Leblond V, Delmer A, Ibach S, Tausch E, Scheffold A, Bloehdorn J, Hallek M, Dreger P, Döhner H, Stilgenbauer S
Telomere length in poor-risk chronic lymphocytic leukemia: associations with disease characteristics and outcome
Leuk Lymphoma. 2017 Oct 24:1. doi: 10.1080/10428194.2017.1390236. [Epub ahead of print]

Tiao G, Improgo MR, Tausch E, Fernandes SM, Bahlo J, Robrecht S, Fischer K, Hallek M, Stilgenbauer S, Kiezun A, Getz G, Brown JR
Analysis of ITGB2 rare germline variants in chronic lymphocytic leukemia
Blood. 2017 Oct 19. pii: blood-2017-08-800128. doi: 10.1182/blood-2017-08-800128. [Epub ahead of print]

Rawstron AC, Kreuzer KA, Soosapilla A, Spacek M, Stehlikova O, Gambell P, McIver-Brown N, Villamor N, Psarra K, Arroz M, Milani R, de la Serna J, Cedena MT, Jaksic O, Nomdedeu J, Moreno C, Rigolin GM, Cuneo A, Johansen P, Johnsen HE, Rosenquist R, Niemann CU, Kern W, Westerman D, Trneny M, Mulligan S, Doubek M, Pospisilova S, Hillmen P, Oscier D, Hallek M, Ghia P, Montserrat E
Reproducible diagnosis of Chronic Lymphocytic Leukemia by flow cytometry: an European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) harmonisation project
Cytometry B Clin Cytom. 2017 Oct 10 doi: 10.1002/cyto.b.21595. [Epub ahead of print]

Al-Sawaf O, Robrecht S, Bahlo J, Fink AM, Cramer P, von Tresckow J, Maurer C, Bergmann M, Seiler T, Lange E, Kneba M, Stilgenbauer S, Döhner H, Kiehl MG, Jäger U, Wendtner CM, Fischer K, Goede V, Hallek M, Eichhorst B, Hopfinger G
Impact of gender on outcome after chemoimmunotherapy in patients with chronic lymphocytic leukaemia: A meta-analysis by the german CLL study group (GCLLSG)
Leukemia. 2017 Oct;31(10):2251-2253

Fink AM, Bahlo J, Robrecht S, Al-Sawaf O, Aldaoud A, Hebart H, Jentsch-Ullrich K, Dörfel S, Fischer K, Wendtner CM, Nösslinger T, Ghia P, Bosch F, Kater AP, Döhner H, Kneba M, Kreuzer KA, Tausch E, Stilgenbauer S, Ritgen M, Böttcher S, Eichhorst B, Hallek M
Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study
Lancet Haematol. 2017 Oct;4(10):e475-e486 doi: 10.1016/S2352-3026(17)30171-0

Wolf C, Garding A, Filarsky K, Bahlo J, Robrecht S, Becker N, Zucknick M, Rouhi A, Weigel A, Claus R, Weichenhan D, Eichhorst B, Fischer K, Hallek M, Kuchenbauer F, Plass C, Döhner H, Stilgenbauer S, Lichter P, Mertens D
NFATC1 activation by DNA hypomethylation in chronic lymphocytic leukemia correlates with clinical staging and can be inhibited by ibrutinib
Int J Cancer. 2017 Sep 18 doi: 10.1002/ijc.31057. [Epub ahead of print]

Krämer I, Stilgenbauer S, Dietrich S, Böttcher S, Zeis M, Stadler M, Bittenbring J, Uharek L, Scheid C, Hegenbart U, Ho A, Hallek M, Kneba M, Schmitz N, Döhner H, Dreger P
Allogeneic hematopoietic cell transplantation for high-risk CLL: 10-year follow-up of the GCLLSG CLL3X trial
Blood. 2017 Sep 21;130(12):1477-1480

Hoechstetter MA, Busch R, Eichhorst B, Bühler A, Winkler D, Eckart MJ, Vehling-Kaiser U, Schimke H, Jäger U, Hurtz HJ, Hopfinger G, Hartmann F, Fuss H, Abenhardt W, Blau I, Freier W, Müller L, Goebeler M, Wendtner C, Bahlo J, Fischer K, Bentz M, Emmerich B, Döhner H, Hallek M, Stilgenbauer S
Early, risk-adapted treatment with fludarabine in binet stage a chronic lymphocytic leukemia patients: Results of the CLL1 trial of the German CLL study group
Leukemia. 2017 Aug 14 [Epub ahead of print]

Klymenko T, Bloehdorn J, Bahlo J, Robrecht S, Akylzhanova G, Cox K, Estenfelder S, Wang J, Edelmann J, Strefford JC, Wojdacz TK, Fischer K, Hallek M, Stilgenbauer S, Cragg M, Gribben J, Braun A
Lamin B1 regulates somatic mutations and progression of B-cell malignancies
Leukemia. 2017 Aug 14 [Epub ahead of print]

Xochelli A, Baliakas P, Kavakiotis I, Agathangelidis A, Sutton LA, Minga E, Ntoufa S, Tausch E, Yan XJ, Shanafelt TD, Plevova K, Boudjogra M, Rossi D, Davis Z, Navarro A, Sandberg Y, Vojdeman FJ, Scarfò L, Stavroyianni N, Sudarikov A, Veronese S, Tzenou T, Karan Djurasevic T, Catherwood MA, Kienle D, Chatzouli M, Facco M, Bahlo J, Pott C, Pedersen LB, Mansouri L, Smedby KE, Chu CC, Giudicelli V, Lefranc MP, Panagiotidis P, Juliusson G, Anagnostopoulos A, Vlahavas I, Antic D, Trentin L, Montillo M, Niemann CU, Dohner H, Langerak AW, Pospisilova S, Hallek M, Campo E, Chiorazzi N, Maglaveras N, Oscier D, Gaidano G, Jelinek DF, Stilgenbauer S, Chouvarda I, Darzentas N, Belessi C, Davi F, Hadzidimitriou A, Rosenquist R, Ghia P, Stamatopoulos K
Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes
Clin Cancer Res. 2017 Sep 1;23(17):5292-5301

Hallek M
Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment
Am J Hematol. 2017 Sep;92(9):946-965

Knittel G, Rehkämper T, Korovkina D, Liedgens P, Fritz C, Torgovnick A, Al-Baldawi Y, Al-Maarri M, Cun Y, Fedorchenko O, Riabinska A, Beleggia F, Nguyen PH, Wunderlich FT, Ortmann M, Montesinos-Rongen M, Tausch E, Stilgenbauer S, P Frenzel L, Herling M, Herling C, Bahlo J, Hallek M, Peifer M, Buettner R, Persigehl T, Reinhardt HC
Two mouse models reveal an actionable PARP1 dependence in aggressive chronic lymphocytic leukemia
Nat Commun. 2017 Jul 28;8(1):153

Tiao G, Improgo MR, Kasar S, Poh W, Kamburov A, Landau DA, Tausch E, Taylor-Weiner A,
Cibulskis C, Bahl S, Fernandes SM, Hoang K, Rheinbay E, Kim HT, Bahlo J, Robrecht S, Fischer K, Hallek M, Gabriel S, Lander ES, Stilgenbauer S, Wu CJ, Kiezun A, Getz G, Brown JR
Rare germline variants in ATM are associated with chronic lymphocytic leukemia
Leukemia. 2017 Jun 27 [Epub ahead of print]

Shanafelt TD, Parikh SA, Noseworthy PA, Goede V, Chaffee KG, Bahlo J, Call TG, Schwager SM, Ding W, Eichhorst B, Fischer K, Leis JF, Chanan-Khan AA, Hallek M, Slager SL, Kay NE
Arial fibrillation in patients with chronic lymphocytic leukemia (CLL)
Leuk Lymphoma. 2017 Jul;58(7):1630-1639

Hallek M
Role and timing of new drugs in CLL
Hematol Oncol. 2017 Jun;35 Suppl 1:30-32

Göckeritz E, Vondey V, Guastafierro A, Pizevska M, Hassenrück F, Neumann L, Hallek M, Krause G
Establishing a chemical genetic link between Bruton tyrosine kinase activity in malignant B cells and cell functions involved in the micro-environmental dialogue
Br J Haematol. 2017 Sep;178(6):949-953 doi: 10.1111/bjh.14781. Epub 2017 Jun 1

Al-Sawaf O, Cramer P, Goede V, Hallek M, Pflug N
Bendamustine and its role in the treatment of unfit patients with chronic lymphocytic leukaemia: a perspective review
Ther Adv Hematol. 2017 Jun;8(6):197-205

Hahn M, Bürckert JP, Luttenberger CA, Klebow S, Hess M, Al-Maarri M, Vogt M, Reißig S, Hallek M, Wienecke-Baldacchino A, Buch T, Muller CP, Pallasch CP, Wunderlich FT, Waisman A, Hövelmeyer N
Aberrant splicing of the tumor suppressor CYLD promotes the development of chronic lymphocytic leukemia via sustained NF-κB signaling
Leukemia. 2017 Jun 1 doi: 10.1038/leu.2017.168. [Epub ahead of print]

Fischer K, Al-Sawaf O, Fink AM, Dixon M, Bahlo J, Warburton S, Kipps TJ, Weinkove R, Robinson S, Seiler T, Opat S, Owen C, López J, Humphrey K, Humerickhouse R, Tausch E, Frenzel L, Eichhorst B, Wendtner CM, Stilgenbauer S, Langerak AW, van Dongen JJ, Boettcher S, Ritgen M, Goede V, Mobasher M, Hallek M
Venetoclax and obinutuzumab in chronic lymphocytic leukemia
Blood. 2017 May 11;129(19):2702-2705

Lohmann G, Vasyutina E, Bloehdorn J, Reinart N, Schneider JI, Babu V, Knittel G, Crispatzu G, Mayer P, Prinz C, Muenzner JK, Biersack B, Efremov DG, Chessa L, Herling CD, Stilgenbauer S, Hallek M, Schobert R, Reinhardt HC, Schumacher B, Herling M
Targeting transcription-coupled nucleotide excision repair overcomes resistance in chronic lymphocytic leukemia
Leukemia. 2017 May;31(5):1177-1186

Jerkeman M, Hallek M, Dreyling M, Thieblemont C, Kimby E, Staudt L
Targeting of B-cell receptor signalling in B-cell malignancies
J Intern Med. 2017 Mar 14 doi: 10.1111/joim.12600. [Epub ahead of print]

Al-Sawaf O, Fischer K, Herling CD, Ritgen M, Böttcher S, Bahlo J, Elter T, Stilgenbauer S, Eichhorst BF, Busch R, Elberskirch U, Abenhardt W, Kneba M, Hallek M, Wendtner CM
Alemtuzumab consolidation in chronic lymphocytic leukaemia: A phase I/II multicentre trial
Eur J Haematol. 2017 Mar;98(3):254-262

Edelmann J, Tausch E, Landau DA, Robrecht S, Bahlo J, Fischer K, Fink AM, Bloehdorn J, Holzmann K, Böttcher S, Werner L, Kneba M, Gribben JG, Neuberg DS, Wu CJ, Hallek M, Döhner H, Stilgenbauer S
Frequent evolution of copy number alterations in CLL following first-line treatment with FC(R) is enriched with TP53 alterations: results from the CLL8 trial
Leukemia. 2017 Mar;31(3):734-738

Reiners KS, Shatnyeva O, Vasyutina E, Bösl T, Hansen HP, Hallek M, Herling M, Pogge von Strandmann E Elke Pogge
Extracellular vesicles released from chronic lymphocytic leukemia cells exhibit a disease relevant mRNA signature and transfer mRNAs to bystander cells
Haematologica. 2017 Mar;102(3):e100-e103

Al-Sawaf O, Fischer K, Engelke A, Pflug N, Hallek M, Goede V
Obinutuzumab in chronic lymphocytic leukemia: design, development and place in therapy
Drug Des Devel Ther. 2017 Jan 25;11:295-304

Kutsch N, Busch R, Bahlo J, Mayer J, Hensel M, Hopfinger G, Hess G, von Grünhagen U, Wendtner CM, Maria Fink A, Fischer K, Hallek M, Eichhorst B
FCR front-line therapy and quality of life in patients with chronic lymphocytic leukemia
Leuk Lymphoma. 2017 Feb;58(2):399-407

2016

Eichhorst B, Hallek M
Prognostication of chronic lymphocytic leukemia in the era of new agents
Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):149-155

Al-Sawaf O, Fischer K, Eichhorst B, Hallek M
Targeted Therapy of CLL
Oncol Res Treat. 2016;39(12):768-778

Vyas M, Schneider AC, Shatnyeva O, Reiners KS, Tawadros S, Kloess S, Köhl U, Hallek M, Hansen HP, Pogge von Strandmann E
Mono- and dual-targeting triplebodies activate natural killer cells and have anti-tumor activity in vitro and in vivo against chronic lymphocytic leukemia
Oncoimmunology. 2016 Jul 15;5(9):e1211220

Nguyen PH, Fedorchenko O, Rosen N, Koch M, Barthel R, Winarski T, Florin A, Wunderlich FT, Reinart N, Hallek M
LYN Kinase in the Tumor Microenvironment Is Essential for the Progression of Chronic Lymphocytic Leukemia
Cancer Cell. 2016 Oct 10;30(4):610-622

Maurer C, Langerbeins P, Bahlo J, Cramer P, Fink AM, Pflug N, Engelke A, von Tresckow J, Kovacs G, Stilgenbauer S, Wendtner CM, Müller L, Ritgen M, Seiler T, Fischer K, Hallek M, Eichhorst B
Effect of first-line treatment on second primary malignancies and Richter's transformation in patients with chronic lymphocytic leukemia (CLL)
Leukemia. 2016 Oct;30(10):2019-2025

Eichhorst B, Robak T, Montserrat E, Ghia P, Hillmen P, Hallek M, Buske C; ESMO Guidelines Committee
eUpdate – Chronic Lymphocytic Leukaemia Treatment Recommendations (ESMO)
Ann Oncol. 2016 Sep;27(suppl 5):v143-v144

Eichhorst B, Hallek M, Goede V
New treatment approaches in CLL: Challenges and opportunities in the elderly
J Geriatr Oncol. 2016 Sep;7(5):375-82

Maurer C, Pflug N, Bahlo J, Kluth S, Rhein C, Cramer P, Gross-Ophoff C, Langerbeins P, Fink AM, Eichhorst B, Kreuzer KA, Fischer N, Tausch E, Stilgenbauer S, Böttcher S, Döhner H, Kneba M, Dreyling M, Binder M, Hallek M, Wendtner CM, Bergmann M, Fischer K; German CLL Study Group
Bendamustine and Rituximab in Combination with Lenalidomide in Patients with Chronic Lymphocytic Leukemia
Eur J Haematol. 2016 Sep;97(3):253-60

Kovacs G, Robrecht S, Fink AM, Bahlo J, Cramer P, von Tresckow J, Maurer C, Langerbeins P, Fingerle-Rowson G, Ritgen M, Kneba M, Döhner H, Stilgenbauer S, Klapper W, Wendtner CM, Fischer K, Hallek M, Eichhorst B, Böttcher S
Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two Phase III Studies of the German CLL Study Group
J Clin Oncol. 2016 Aug 29. pii: JCO671305. [Epub ahead of print]

Louise Freeman C, Dixon M, Houghton R, Kreuzer KA, Fingerle-Rowson G, Herling M, Humphrey K, Böttcher S, de Costa CS, Iglesias V, Stilgenbauer S, Gribben J, Hallek M,
Goede V
Role of CD20 expression and other pre-treatment risk factors in the development of infusion-related reactions in patients with CLL treated with obinutuzumab
Leukemia. 2016 Aug;30(8):1763-6

Scheffold A, Jebaraj BM, Jaramillo S, Tausch E, Steinbrecher D, Hahn M, Böttcher S, Ritgen M, Bunjes D, Zeis M, Stadler M, Uharek L, Scheid C, Hegenbart U, Hallek M, Kneba M, Schmitz N, Döhner H, Dreger P, Stilgenbauer S
Impact of telomere length on the outcome of allogeneic stem cell transplantation for poor-risk chronic lymphocytic leukaemia: results from the GCLLSG CLL3X trial
Br J Haematol. 2016 Jul 8 [Epub ahead of print]

Thijssen R, Ter Burg J, Garrick B, van Bochove GG, Brown JR, Fernandes SM, Rodríguez MS, Michot JM, Hallek M, Eichhorst B, Reinhardt HC, Bendell J, Derks IA, van Kampen RJ, Hege K, Kersten MJ, Trowe T, Filvaroff EH, Eldering E, Kater AP
Dual TORK/DNA-PK inhibition blocks critical signalling pathways in chronic lymphocytic leukemia
Blood. 2016 Jul 28;128(4):574-83

Herling CD, Klaumünzer M, Krings Rocha C, Altmüller J, Thiele H, Bahlo J, Kluth S, Crispatzu G, Herling M, Schiller J, Engelke A, Tausch E, Döhner H, Fischer K, Goede V, Nürnberg P, Reinhardt HC, Stilgenbauer S, Hallek M, Kreuzer KA
Complex karyotypes, KRAS and POT1 mutations impact outcome in CLL after chlorambucil based chemo- or chemoimmunotherapy
Blood. 2016 Jul 21;128(3):395-404

Eichhorst B, Fink AM, Bahlo J, Busch R, Kovacs G, Maurer C, Lange E, Köppler H, Kiehl M, Sökler M, Schlag R, Vehling-Kaiser U, Köchling G, Plöger C, Gregor M, Plesner T, Trneny M, Fischer K, Döhner H, Kneba M, Wendtner CM, Klapper W, Kreuzer KA, Stilgenbauer S, Böttcher S, Hallek M; international group of investigators; German CLL Study Group (GCLLSG)
First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial
Lancet Oncol. 2016 Jul;17(7):928-42

The International CLL-IPI working group
An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data
Lancet Oncol. 2016 Jun;17(6):779-90
CLL-IPI Online Calculator

Stilgenbauer S, Eichhorst B, Schetelig J, Coutre S, Seymour JF, Munir T, Puvvada SD, Wendtner CM, Roberts AW, Jurczak W, Mulligan SP, Böttcher S, Mobasher M, Zhu M, Desai M, Chyla B, Verdugo M, Enschede SH, Cerri E, Humerickhouse R, Gordon G, Hallek M, Wierda WG
Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study
Lancet Oncol. 2016 Jun;17(6):768-78

Brown JR, Hallek MJ, Pagel JM
Chemoimmunotherapy Versus Targeted Treatment in Chronic Lymphocytic Leukemia: When, How Long, How Much, and in Which Combination?
Am Soc Clin Oncol Educ Book. 2016;35:e387-98

Lilienthal N, Lohmann G, Crispatzu G, Vasyutina E, Zittrich S, Mayer P, Herling CD, Tur MK, Hallek M, Pfitzer G, Barth S, Herling M
A Novel Recombinant Anti-CD22 Immunokinase Delivers Proapoptotic Activity of Death-Associated Protein Kinase (DAPK) and Mediates Cytotoxicity in Neoplastic B Cells
Mol Cancer Ther. 2016 May;15(5):971-84

Cramer P, Langerbeins P, Fischer K, Eichhorst B, Hallek M, Goede V
Dose-reduced fludarabine, cyclophosphamide and rituximab (FCR) in older patients with chronic lymphocytic leukemia: does one size fit all?
Leuk Lymphoma. 2016 May;57(5):987-990

Lilienthal N, Lohmann G, Crispatzu G, Vasyutina E, Zittrich S, Mayer P, Herling CD, Tur MK, Hallek M, Pfitzer G, Barth S, Herling M
A novel recombinant anti-CD22 immunokinase delivers pro-apoptotic activity of death-associated protein kinase (DAPK) and mediates cytotoxicity in neoplastic B-cells
Mol Cancer Ther. 2016 May;15(5):971-84

Müller D, Fischer K, Kaiser P, Eichhorst B, Walshe R, Reiser M, Kellermann L, Borsi L, Civello D, Mensch A, Bahlo J, Hallek M, Stock S, Fingerle-Rowson G
Cost-effectiveness of rituximab in addition to fludarabine and cyclophosphamide (R-FC) for the first-line treatment of chronic lymphocytic leukemia
Leuk Lymphoma. 2016 May;57(5):1130-9

Pflug N, Kluth S, Vehreschild JJ, Bahlo J, Tacke D, Biehl L, Eichhorst B, Fischer K, Cramer P, Fink AM, von Bergwelt-Baildon M, Stilgenbauer S, Hallek M, Cornely OA, Vehreschild MJ
Efficacy of antineoplastic treatment is associated with the use of antibiotics that modulate intestinal microbiota
Oncoimmunology. 2016 Apr 22;5(6):e1150399

Eichhorst B, Cramer P, Hallek M
Initial therapy of chronic lymphocytic leukemia
Semin Oncol. 2016 Apr;43(2):241-50

Hellmich S, Schreiber N, Fath B, Hallek M
Fortschritt durch vernetzte Strukturen: Herausforderungen für das Kompetenznetz Maligne Lymphome im Zeitalter der Präzisionsmedizin
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2016 Apr;59(4):454-64

Goede V, Bahlo J, Chataline V, Eichhorst B, Dürig J, Stilgenbauer S, Kolb G, Honecker F, Wedding U, Hallek M
Evaluation of geriatric assessment in patients with chronic lymphocytic leukemia: Results of the CLL9 trial of the German CLL Study Group
Leuk Lymphoma. 2016 Apr;57(4):789-96

Rawstron AC, Fazi C, Agathangelidis A, Villamor N, Letestu R, Nomdedeu J, Palacio C, Stehlikova O, Kreuzer KA, Liptrot S, O'Brien D, de Tute RM, Marinov I, Hauwel M, Spacek M, Dobber J, Kater AP, Gambell P, Soosapilla A, Lozanski G, Brachtl G, Lin K, Boysen J, Hanson C, Jorgensen JL, Stetler-Stevenson M, Yuan C, Broome HE, Rassenti L, Craig F, Delgado J, Moreno C, Bosch F, Egle A, Doubek M, Pospisilova S, Mulligan S, Westerman D, Sanders CM, Emerson R, Robins HS, Kirsch I, Shanafelt T, Pettitt A, Kipps TJ, Wierda WG, Cymbalista F, Hallek M, Hillmen P, Montserrat E, Ghia P
A complementary role of multiparameter flow-cytometry and high-throughput sequencing for minimal residual disease (MRD) detection in chronic lymphocytic leukemia (CLL): An european research initiative on CLL (ERIC) study
Leukemia. 2016 Apr;30(4):929-36

Goede V, Busch R, Bahlo J, Chataline V, Kremers S, Müller L, Reschke D, Schlag R, Schmidt B, Vehling-Kaiser U, Wedding U, Stilgenbauer S, Hallek M
Low-dose fludarabine with or without darbepoetin alfa in patients with chronic lymphocytic leukemia and comorbidity: Primary results of the CLL9 trial of the German CLL Study Group
Leuk Lymphoma. 2016 Mar;57(3):596-603

Cramer P, Eichhorst B, Reinhardt HC, Hallek M
Current strategies to create tailored and risk-adapted therapies for CLL patients
Best Pract Res Clin Haematol. 2016 Mar;29(1):111-121

Bühler A, Wendtner CM, Kipps TJ, Rassenti L, Fraser GA, Michallet AS, Hillmen P, Dürig J, Gregory SA, Kalaycio M, Aurran-Schleinitz T, Trentin L, Gribben JG, Chanan-Khan A, Purse B, Zhang J, De Bedout S, Mei J, Hallek M, Stilgenbauer S
Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial
Blood Cancer J. 2016 Mar 11;6:e404

Cramer P, Hallek M, Eichhorst B
State-of-the-Art Treatment and Novel Agents in Chronic Lymphocytic Leukemia
Oncol Res Treat. 2016;39(1-2):25-32

Langerbeins P, Groß-Ophoff-Müller C, Herling CD
Risk-Adapted Therapy in Early-Stage Chronic Lymphocytic Leukemia
Oncol Res Treat. 2016;39(1-2):18-24

Frenzel LP, Reinhardt HC, Pallasch CP
Concepts of Chronic Lymphocytic Leukemia Pathogenesis: DNA Damage Response and Tumor Microenvironment
Oncol Res Treat. 2016;39(1-2):9-16

Cramer P, Langerbeins P, Hallek M
Combination of Targeted Drugs to Control Chronic Lymphocytic Leukemia: Harnessing the Power of New Monoclonal Antibodies in Combination With Ibrutinib
Cancer J. 2016 Jan-Feb;22(1):62-66

Chanan-Khan A, Cramer P, Demirkan F, Fraser G, Silva RS, Grosicki S, Pristupa A, Janssens A, Mayer J, Bartlett NL, Dilhuydy MS, Pylypenko H, Loscertales J, Avigdor A, Rule S, Villa D, Samoilova O, Panagiotidis P, Goy A, Mato A, Pavlovsky MA, Karlsson C, Mahler M, Salman M, Sun S, Phelps C, Balasubramanian S, Howes A, Hallek M; HELIOS investigators
Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study
Lancet Oncol. 2016 Feb;17(2):200-11

Fischer K, Bahlo J, Fink AM, Goede V, Herling CD, Cramer P, Langerbeins P, von Tresckow J, Engelke A, Maurer C, Kovacs G, Herling M, Tausch E, Kreuzer KA, Eichhorst B, Böttcher S, Seymour JF, Ghia P, Marlton P, Kneba M, Wendtner CM, Döhner H, Stilgenbauer S, Hallek M
Long term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial
Blood. 2016 Jan 14;127(2):208-15

Cramer P, Langerbeins P, Eichhorst B, Hallek M
Advances in first-line treatment of chronic lymphocytic leukemia current recommendations on management and first-line treatment by the German CLL Study Group (GCLLSG)
Eur J Haematol. 2016 Jan;96(1):9-18

2015

Kirsten Fischer, Anna-Maria Fink, Helen Bishop, Mark Dixon, Jasmin Bahlo, Michael Y. Choi, Robert Weinkove, K. Sue Robinson, Martin Dreyling, Till Seiler, Stephen Opat, Carolyn Owen, Javier Lopez Sr., Nadine Kutsch, Eugen Tausch, Matthias Ritgen, Rod A. Humerickhouse, Kathryn Humphrey, Michael K. Wenger, Valentin Goede, Barbara Eichhorst, Clemens-Martin Wendtner, Stephan Stilgenbauer, Thomas J. Kipps and Michael Hallek
Results of the Safety Run-in Phase of CLL14 (BO25323): A Prospective, Open-Label, Multicenter Randomized Phase III Trial to Compare the Efficacy and Safety of Obinutuzumab and Venetoclax (GDC-0199/ABT-199) with Obinutuzumab and Chlorambucil in Patients with Previously Untreated CLL and Coexisting Medical Conditions (ASH Abstract)
Blood 2015 Dec 03;126(23):496

Cramer P, Isfort S, Bahlo J, Stilgenbauer S, Döhner H, Bergmann M, Stauch M, Kneba M, Lange E, Langerbeins P, Pflug N, Kovacs G, Goede V, Fink AM, Elter T, Fischer K, Wendtner CM, Hallek M, Eichhorst B
Outcome of advanced chronic lymphocytic leukemia following different firstline- and relapse-therapies: A metaanalysis of five prospective trials of german CLL study group (GCLLSG)
Haematologica. 2015 Nov;100(11):1451-9

Göckeritz E, Kerwien S, Baumann M, Wigger M, Vondey V, Neumann L, Landwehr T, Wendtner CM, Klein C, Liu N, Hallek M, Frenzel LP, Krause G
Efficacy of phosphatidylinositol-3 kinase inhibitors with diverse isoform selectivity profiles for inhibiting the survival of chronic lymphocytic leukemia cells
Int J Cancer. 2015 Nov 1;137(9):2234-42

Landau DA, Tausch E, Taylor-Weiner AN, Stewart C, Reiter JG, Bahlo J, Kluth S, Bozic I, Lawrence M, Böttcher S, Carter SL, Cibulskis K, Mertens D, Sougnez CL, Rosenberg M, Hess JM, Edelmann J, Kless S, Kneba M, Ritgen M, Fink A, Fischer K, Gabriel S, Lander ES, Nowak MA, Döhner H, Hallek M, Neuberg D, Getz G, Stilgenbauer S, Wu CJ
Mutations driving CLL and their evolution in progression and relapse
Nature. 2015 Oct 22;526(7574):525-30

Goede V, Hallek M
Pharmacotherapeutic Management of Chronic Lymphocytic Leukaemia in Patients with Comorbidities: New Agents, New Hope
Drugs Aging. 2015 Nov;32(11):877-86

Göckeritz E, Kerwien S, Baumann M, Wigger M, Vondey V, Neumann L, Landwehr T, Wendtner CM, Klein C, Liu N, Hallek M, Frenzel LP, Krause G
Efficacy of phosphatidylinositol-3 kinase inhibitors with diverse isoform selectivity profiles for inhibiting the survival of chronic lymphocytic leukemia cells
Int J Cancer. 2015 Nov 1;137(9):2234-42

Chakupurakal G, Leitzke S, Langerbeins P, Schiller J, Schneider PM, Holtick U, Shimabukuro-Vornhagen A, Theurich S, Chemnitz J, Hallek M, von Bergwelt-Baildon M, Scheid C
Nonmyeloablative allogeneic stem cell transplantation for chronic lymphocytic leukaemia offers the possibility of disease control with minimal morbidity and mortality-a single institution experience

Ann Hematol. 2015 Oct;94(10):1717-25

Eichhorst B, Robak T, Montserrat E, Ghia P, Hillmen P, Hallek M, Buske C; ESMO Guidelines Committee
Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Ann Oncol. 2015 Sep;26 Suppl 5:v78-v84

Langerbeins P, Bahlo J, Rhein C, Cramer P, Pflug N, Fischer K, Stilgenbauer S, Kreuzer KA, Wendtner CM, Eichhorst B, Hallek M
The CLL12 trial protocol: a placebo-controlled double-blind Phase III study of ibrutinib in the treatment of early-stage chronic lymphocytic leukemia patients with risk of early disease progression
Future Oncol. 2015 Jul;11(13):1895-903

Goede V, Fischer K, Engelke A, Schlag R, Lepretre S, Montero LF, Montillo M, Fegan C, Asikanius E, Humphrey K, Fingerle-Rowson G, Hallek M
Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: Updated results of the CLL11 study
Leukemia. 2015 Jul;29(7):1602-4

Schrader A, Popal W, Lilienthal N, Crispatzu G, Mayer P, Jones D, Hallek M, Herling M
AKT-pathway inhibition in chronic lymphocytic leukemia reveals response relationships defined by TCL1
Curr Cancer Drug Targets. 2014;14(8):700-12

Vollbrecht C, Mairinger FD, Koitzsch U, Peifer M, Koenig K, Heukamp LC, Crispatzu G, Wilden L, Kreuzer KA, Hallek M, Odenthal M, Herling CD, Buettner R
Comprehensive Analysis of Disease-Related Genes in Chronic Lymphocytic Leukemia by Multiplex PCR-Based Next Generation Sequencing
PLoS One. 2015 Jun 8;10(6):e0129544

Goede V, Eichhorst B, Fischer K, Wendtner CM, Hallek M
Past, present and future role of chlorambucil in the treatment of chronic lymphocytic leukemia
Leuk Lymphoma. 2015 Jun;56(6):1585-92

Prinz C, Vasyutina E, Lohmann G, Schrader A, Romanski S, Hirschhäuser C, Mayer P, Frias C, Herling CD, Hallek M, Schmalz HG, Prokop A, Mougiakakos D, Herling M
Organometallic nucleosides induce non-classical leukemic cell death that is mitochondrial-ROS dependent and facilitated by TCL1-oncogene burden
Mol Cancer. 2015 Jun 4;14(1):114

Holtick U, Chemnitz JM, Hallek M, Scheid C
Allogene Blutstammzelltransplantation – ein Überblick
Klin Monbl Augenheilkd. 2015 May;232(5):641-6

Hallek M
Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment
Am J Hematol. 2015 May;90(5):446-60

Goede V, Hallek M
Towards improved frontline treatment of CLL in the elderly
Lancet. 2015 May 9;385(9980):1814-5

Berg V, Rusch M, Vartak N, Jüngst C, Schauss A, Waldmann H, Hedberg C, Pallasch CP, Bastiaens PI, Hallek M, Wendtner CM, Frenzel LP
miRs-138 and -424 control palmitoylation-dependent CD95-mediated cell death by targeting acyl protein thioesterases 1 and 2 in chronic lymphocytic leukemia
Blood. 2015 May 7;125(19):2948-57

Langerbeins P, Maurer C, Cramer P, Eichhorst B, Hallek M
Second cancers in chronic lymphocytic leukemia: Growing importance in the era of improved treatment outcomes
Leuk Lymphoma. 2015 May 12:1-2

Hallek M
Klinische Forschung in Deutschland: Bürokratieabbau jetzt wagen!
Dtsch Med Wochenschr. 2015 Apr;140(7):463-4

Eichhorst B, Hallek M
Erratum zu: Chronische lymphatische Leukämie.Therapiekonzepte im Wandel
Internist (Berl). 2017 Aug 18 [Epub ahead of print]

Eichhorst B, Hallek M
Chronische lymphatische Leukämie - Therapiekonzepte im Wandel
Internist (Berl). 2015 Apr;56(4):374-80

Kutsch N, Hallek M, Eichhorst B
Emerging therapies for refractory CLL
Leuk Lymphoma. 2015 Feb;56(2):285-92

2014

Stilgenbauer S, Cymbalista F, Leblond V, Delmer A, Ibach S, Choquet S, Dartigeas C, Cazin B, Tournilhac O, Pegourie B, Seiler TM, Sökler M, Zirlik K, Alt J, Huber H, Bloehdorn J, Tausch E, Zenz T, Hallek M, Schetelig J, Dreger P, Döhner H
Alemtuzumab combined with dexamethasone, followed by alemtuzumab maintenance or Allo-SCT in “ultra High-risk” CLL: final results from the CLL2O phase II study
Blood. 2014;124:1991

Langerbeins P, Busch R, Anheier N, Dürig J, Bergmann M, Goebeler ME, Hurtz HJ, Stauch MB, Stilgenbauer S, Döhner H, Fink AM, Cramer P, Fischer K, Wendtner CM, Hallek M, Eichhorst B
Poor efficacy and tolerability of R-CHOP in relapsed/refractory chronic lymphocytic leukemia and Richter transformation
Am J Hematol. 2014 Dec;89(12):E239-43

Dreger P, Schetelig J, Andersen N, Corradini P, van Gelder M, Gribben J, Kimby E, Michallet M, Moreno C, Stilgenbauer S, Montserrat E; European Research Initiative on CLL (ERIC) and the European Society for Blood and Marrow Transplantation (EBMT)
Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?
Blood. 2014 Dec 18;124(26):3841-9

Pallasch CP, Hallek M
Incorporating targeted agents into future therapy of chronic lymphocytic leukemia
Semin Hematol. 2014 Jul;51(3):235-48

Weisser M, Yeh RF, Duchateau-Nguyen G, Palermo G, Nguyen TQ, Shi X, Stinson SY, Yu N, Dufour A, Robak T, Salogub GN, Dmoszynska A, Solal-Celigny P, Warzocha K, Loscertales J, Catalano J, Larratt L, Rossiev VA, Bence-Bruckler I, Geisler CH, Montillo M, Fischer K, Fink AM, Hallek M, Bloehdorn J, Busch R, Benner A, Döhner H, Valente N, Wenger MK, Stilgenbauer S, Dornan D
PTK2 expression and immunochemotherapy outcome in chronic lymphocytic leukemia
Blood. 2014 Jul 17;124(3):420-5

Pflug N, Bahlo J, Shanafelt TD, Eichhorst BF, Bergmann MA, Elter T, Bauer K, Malchau G, Rabe KG, Stilgenbauer S, Döhner H, Jäger U, Eckart MJ, Hopfinger G, Busch R, Fink AM, Wendtner CM, Fischer K, Kay NE, Hallek M
Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia
Blood. 2014 Jul 3;124(1):49-62

Goede V, Cramer P, Busch R, Bergmann M, Stauch M, Hopfinger G, Stilgenbauer S, Doehner H, Westermann A, Wendtner CM, Eichhorst B, Hallek M
Interactions between comorbidity and treatment of chronic lymphocytic leukemia: results of German Chronic Lymphocytic Leukemia Study Group trials
Haematologica. 2014 Jun;99(6):1095-100

Ghia P, Hallek M
Management of chronic lymphocytic leukemia
Haematologica. 2014 Jun;99(6):965-972

Stilgenbauer S, Schnaiter A, Paschka P, Zenz T, Rossi M, Döhner K, Bühler A, Böttcher S, Ritgen M, Kneba M, Winkler D, Tausch E, Hoth P, Edelmann J, Mertens D, Bullinger L, Bergmann M, Kless S, Mack S, Jäger U, Patten N, Wu L, Wenger MK, Fingerle-Rowson G, Lichter P, Cazzola M, Wendtner CM, Fink AM, Fischer K, Busch R, Hallek M, Döhner H
Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial
Blood. 2014 May 22;123(21):3247-54

Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, Chagorova T, de la Serna J, Dilhuydy MS, Illmer T, Opat S, Owen CJ, Samoylova O, Kreuzer KA, Stilgenbauer S, Döhner H, Langerak AW, Ritgen M, Kneba M, Asikanius E, Humphrey K, Wenger M, Hallek M
Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions
N Engl J Med. 2014 Mar 20;370(12):1101-10

2013

Cramer P, Bahlo J, Eichhorst B, Fischer K, Hallek M
Extramedullary manifestations of chronic lymphocytic leukaemia are not unusual
Leuk Res. 2013 Dec 1. pii: S0145-2126(13)00416-5

Hallek M
Signaling the end of chronic lymphocytic leukemia: new frontline treatment strategies
Hematology Am Soc Hematol Educ Program. 2013;2013:138-50
Blood
. 2013 Nov 28;122(23):3723-34

Maurer C, Hallek M
Chronische lymphatische Leukämie
Dtsch Med Wochenschr. 2013 Oct;138(42):2153-66

Hallek M
Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment
Am J Hematol. 2013 Sep;88(9):803-16

Fink AM, Böttcher S, Ritgen M, Fischer K, Pflug N, Eichhorst B, Wendtner CM, Winkler D, Bühler A, Zenz T, Staib P, Mayer J, Hensel M, Hopfinger G, Wenger M, Fingerle-Rowson G, Döhner H, Kneba M, Stilgenbauer S, Busch R, Hallek M
Prediction of poor outcome in CLL patients following first-line treatment with fludarabine, cyclophosphamide and rituximab
Leukemia. 2013 Sep;27(9):1949-52

Göbel M, Eisele L, Möllmann M, Hüttmann A, Johansson P, Scholtysik R, Bergmann M, Busch R, Döhner H, Hallek M, Seiler T, Stilgenbauer S, Klein-Hitpass L, Dührsen U, Dürig J
Progranulin is a novel independent predictor of disease progression and overall survival in chronic lymphocytic leukemia
PLoS One. 2013 Aug 23;8(8):e72107

Schnaiter A, Paschka P, Rossi M, Zenz T, Bühler A, Winkler D, Cazzola M, Döhner K, Edelmann J, Mertens D, Kless S, Mack S, Busch R, Hallek M, Döhner H, Stilgenbauer S
NOTCH1, SF3B1 and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: results from the CLL2H trial of the GCLLSG
Blood. 2013 Aug 15;122(7):1266-70

Cramer P, Fink AM, Busch R, Eichhorst B, Wendtner C, Pflug N, Langerbeins P, Bahlo J, Goede V, Schubert F, Döhner H, Stigenbauer S, Dreger P, Kneba M, Böttcher S, Mayer J, Hallek M, Fischer K
Second-line Therapies of Patients initially treated with Fludarabine and Cyclophosphamide (FC) or Fludarabine, Cyclophosphamide and Rituximab (FCR) for Chronic Lymphocytic Leukemia (CLL) within the CLL8-Protocol of the German CLL Study Group (GCLLSG)
Leuk Lymphoma. 2013 Aug;54(8):1821-2

Hopfinger G, Busch R, Pflug N, Weit N, Westermann A, Fink AM, Cramer P, Reinart N, Winkler D, Fingerle-Rowson G, Stilgenbauer S, Döhner H, Kandler G, Eichhorst B, Hallek M, Herling M
Sequential chemoimmunotherapy of fludarabine, mitoxantrone, and cyclophosphamide induction followed by alemtuzumab consolidation is effective in T-cell prolymphocytic leukemia
Cancer. 2013 Jun 15;119(12):2258-67

Goede V, Fischer K, Busch R, Jaeger U, Dilhuydy MS, Wickham N, De Guibert S, Ritgen M, Langerak AW, Bieska G, Engelke A, Humphrey K, Wenger M, Hallek M
Chemoimmunotherapy with GA101 plus chlorambucil in patients with chronic lymphocytic leukemia and comorbidity: results of the CLL11 (BO21004) safety run-in
Leukemia. 2013 Apr;27(5):1172-4

Dreger P, Schnaiter A, Zenz T, Böttcher S, Rossi M, Paschka P, Bühler A, Dietrich S, Busch R, Ritgen M, Bunjes D, Zeis M, Stadler M, Uharek L, Scheid C, Hegenbart U, Hallek M, Kneba M, Schmitz N, Döhner H, Stilgenbauer S
TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial
Blood. 2013 Apr 18;121(16):3284-8

Hallek M, Knauf W, Dreyling M, Trümper L
Aktuelle und künftige Indikationen mit Bendamustin: chronische lymphatische Leukämie, indolente Lymphome, Mantelzell-Lymphome und diffuse großzellige B-Zell-Lymphome
Onkologie. 2013;36 Suppl 1:11-8

Stilgenbauer S, Hallek M
Chronische lymphatische Leukämie: Therapie und genetisches Risikoprofil
Internist (Berl). 2013 Feb;54(2):164-70

 

2012

Elter T, James R, Busch R, Winkler D, Ritgen M, Böttcher S, Kahl C, Gassmann W, Stauch M, Hasan I, Staib P, Fischer K, Fink AM, Bahlo J, Bühler A, Döhner H, Wendtner CM, Stilgenbauer S, Engert A, Hallek M writtrn on behalf of the German Chronic Lymphocytic Leukemia Study Group (GCLLSG)
Fludarabine and cyclophosphamide in combination with alemtuzumab (FCCam) in patients with primary high-risk, relapsed or refractory chronic lymphocytic leukemia
Leukemia. 2012 Dec;26(12):2549-52

Edelmann J, Holzmann K, Miller F, Winkler D, Bühler A, Zenz T, Bullinger L, Kühn MW, Gerhardinger A, Bloehdorn J, Radtke I, Su X, Ma J, Pounds S, Hallek M, Lichter P, Korbel J, Busch R, Mertens D, Downing JR, Stilgenbauer S, Döhner H
High-resolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterations
Blood. 2012 Dec 6;120(24):4783-94

Fischer K, Cramer P, Busch R, Böttcher S, Bahlo J, Schubert J, Pflüger KH, Schott S, Goede V, Isfort S, von Tresckow J, Fink AM, Bühler A, Winkler D, Kreuzer KA, Staib P, Ritgen M, Kneba M, Döhner H, Eichhorst BF, Hallek M, Stilgenbauer S, Wendtner CM
Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group
J Clin Oncol. 2012 Sep 10;30(26):3209-16

Köppler H, Fuss H, Hurtz HJ, Knigge O, Losem C, Reschke D, Schmitz S, Weide R, Weiß J, Hallek M; for the GCLLSG
Bendamustine plus mitoxantrone for relapsed/refractory chronic lymphocytic leukaemia (CLL): results of a multicentre phase II study of the German CLL Study Group (GCLLSG)
Br J Haematol. 2012 Jul;158(2):238-41

Isfort S, Cramer P, Hallek M
Novel and emerging drugs for chronic lymphocytic leukemia
Curr Cancer Drug Targets. 2012 Jun;12(5):471-83

Dreger P, Döhner H, McClanahan F, Busch R, Ritgen M, Greinix H, Fink AM, Knauf W, Stadler M, Pfreundschuh M, Dührsen U, Brittinger G, Hensel M, Schetelig J, Winkler D, Bühler A, Kneba M, Schmitz N, Hallek M, Stilgenbauer S
Early autologous stem cell transplantation for chronic lymphocytic leukemia: long-term follow-up of the GCLLSG CLL3 trial
Blood. 2012 May 24;119(21):4851-4859

Zenz T, Gribben JG, Hallek M, Döhner H, Keating MJ, Stilgenbauer S.
Risk categories and refractory CLL in the era of chemoimmunotherapy
Blood. 2012 May 3;119(18):4101-7

Böttcher S, Ritgen M, Fischer K, Stilgenbauer S, Busch RM, Fingerle-Rowson G, Fink AM, Bühler A, Zenz T, Wenger MK, Mendila M, Wendtner CM, Eichhorst BF, Döhner H, Hallek MJ, Kneba M.
Minimal Residual Disease Quantification Is an Independent Predictor of Progression-Free and Overall Survival in Chronic Lymphocytic Leukemia: A Multivariate Analysis From the Randomized GCLLSG CLL8 Trial
J Clin Oncol. 2012 Mar 20;30(9):980-8

Skoetz N, Bauer K, Elter T, Monsef I, Roloff V, Hallek M, Engert A.
Alemtuzumab for patients with chronic lymphocytic leukaemia
Cochrane Database Syst Rev. 2012 Feb 15;2:CD008078

 

2011

Fischer K, Cramer P, Busch R, Stilgenbauer S, Bahlo J, Schweighofer CD, Böttcher S, Staib P, Kiehl M, Eckart MJ, Kranz G, Goede V, Elter T, Bühler A, Winkler D, Kneba M, Döhner H, Eichhorst BF, Hallek M, Wendtner CM
Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the german chronic lymphocytic leukemia study group
J Clin Oncol. 2011 Sep 10;29(26):3559-66

Eichhorst B, Dreyling M, Robak T, Montserrat E, Hallek M; ESMO Guidelines Working Group
Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Ann Oncol. 2011 Sep;22 Suppl 6:vi50-4

Eichhorst BF, Fischer K, Fink AM, Elter T, Wendtner CM, Goede V, Bergmann M, Stilgenbauer S, Hopfinger G, Ritgen M, Bahlo J, Busch R, Hallek M
Limited clinical relevance of imaging techniques in the follow-up of patients with advanced chronic lymphocytic leukemia: results of a meta-analysis
Blood. 2011 Feb 10;117(6):1817-21

Michallet M, Dreger P, Sutton L, Brand R, Richards S, van Os M, Sobh M, Choquet S, Corront B, Dearden C, Gratwohl A, Herr W, Catovsky D, Hallek M, de Witte T, Niederwieser D, Leporrier M, Milligan D
Autologous hematopoietic stem cell transplantation in chronic lymphocytic leukemia: results of European intergroup randomized trial comparing autografting versus observation
Blood. 2011 Feb 3;117(5):1516-21

Hallek M, Pflug N
State of the art treatment of chronic lymphocytic leukaemia
Blood Rev. 2011 Jan;25(1):1-9

Cramer P, Hallek M.
Prognostic factors in chronic lymphocytic leukemia-what do we need to know?
Nat Rev Clin Oncol. 2011 Jan;8(1):38-47. Review

 

2010

Zenz T, Eichhorst B, Busch R, Denzel T, Häbe S, Winkler D, Bühler A, Edelmann J, Bergmann M, Hopfinger G, Hensel M, Hallek M, Döhner H, Stilgenbauer S
TP53 mutation and survival in chronic lymphocytic leukemia
J Clin Oncol. 2010 Oct 10;28(29):4473-9

Dreger P, Döhner H, Ritgen M, Böttcher S, Busch R, Dietrich S, Bunjes D, Cohen S, Schubert J, Hegenbart U, Beelen D, Zeis M, Stadler M, HasenkampJ, Uharek L, Scheid C, Humpe A, Zenz T, Winkler D, Hallek M,Kneba M, Schmitz N, Stilgenbauer S.
Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the GCLLSG CLL3X trial
Blood. 2010 Oct 7;116(14):2438-47

Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, Hensel M, Hopfinger G, Hess G, von Grünhagen U, Bergmann M, Catalano J, Zinzani PL, Caligaris-Cappio F, Seymour JF, Berrebi A, Jäger U, Cazin B, Trneny M, Westermann A, Wendtner CM, Eichhorst BF, Staib P, Bühler A, Winkler D, Zenz T, Böttcher S, Ritgen M, Mendila M, Kneba M, Döhner H, Stilgenbauer S; International Group of Investigators; German Chronic Lymphocytic Leukaemia Study Group.
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
Lancet. 2010 Oct 2;376(9747):1164-74

Schweighofer CD, Wendtner CM.
First-line treatment of chronic lymphocytic leukemia: role of alemtuzumab
Onco Targets Ther. 2010 Jun 24;3:53-67

 

2009

Hallek M.
State-of-the-art treatment of chronic lymphocytic leukemia
Hematology Am Soc Hematol Educ Program. 2009:440-9. Review

Dreger P.
Allotransplantation for chronic lymphocytic leukemia
Hematology Am Soc Hematol Educ Program. 2009:602-9. Review.

Böttcher S, Stilgenbauer S, Busch R, Brüggemann M, Raff T, Pott C, Fischer K, Fingerle-Rowson G, Döhner H, Hallek M, Kneba M, Ritgen M.
Standardized MRD flow and ASO IGH RQ-PCR for MRD quantification in CLL patientsafter rituximab-containing immunochemotherapy: a comparative analysis
Leukemia. 2009 Nov;23(11):2007-17

Eichhorst BF, Busch R, Stilgenbauer S, Stauch M, Bergmann MA, Ritgen M, Kranzhofer N, Rohrberg R, Soling U, Burkhard O, Westermann A, Goede V, Schweighofer CD, Fischer K, Fink AM, Wendtner CM, Brittinger G, Dohner H, Emmerich B, Hallek M; German CLL Study Group (GCLLSG)
First line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia
Blood 2009 Oct 15;114(16):3382-91

Zenz T, Häbe S, Denzel T, Mohr J, Winkler D, Bühler A, Sarno A, Groner S, Mertens D, Busch R, Hallek M, Döhner H, Stilgenbauer S
Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial
Blood. 2009 Sep 24;114(13):2589-97

Stilgenbauer S, Zenz T, Winkler D, Bühler A, Schlenk RF, Groner S, Busch R, Hensel M, Dührsen U, Finke J, Dreger P, Jäger U, Lengfelder E, Hohloch K, Söling U, Schlag R, Kneba M, Hallek M, Döhner H; German Chronic Lymphocytic Leukemia Study Group
Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group
J Clin Oncol. 2009 Aug 20;27(24):3994-4001

Eichhorst B, Goede V, Hallek M.
Treatment of elderly patients with chronic lymphocytic leukemia
Leuk Lymphoma. 2009 Feb;50(2):171-8

Schweighofer CD, Ritgen M, Eichhorst BF, Busch R, Abenhardt W, Kneba M, Hallek M, Wendtner CM
Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG)
Br J Haematol. 2009 Jan;144(1):95-8

 

2008

Ritgen M, Böttcher S, Stilgenbauer S, Bunjes D, Schubert J, Cohen S, Humpe A, Hallek M, Kneba M, Schmitz N, Döhner H, Dreger P; German CLL Study Group
Quantitative MRD monitoring identifies distinct GVLresponse patterns after allogeneic stem cell transplantation for chronic lymphocytic leukemia: results from the GCLLSG CLL3X trial
Leukemia. 2008 Jul;22(7):1377-86

Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, Hillmen P, Keating MJ, Montserrat E, Rai KR, Kipps TJ; International Workshop on Chronic Lymphocytic Leukemia.
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the InternationalWorkshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines
Blood. 2008 Jun 15;111(12):5446-56
(Erratum in Blood. 2008 Dec 15;112(13):5259)

Hallek M; German CLL Study Group
Prognostic factors in chronic lymphocytic leukemia
Ann Oncol. 2008 Jun;19 Suppl 4:iv51-3

 

2007

Eichhorst BF, Busch R, Stauch M, Bergmann M, Ritgen M, Kranzhöfer N, Schweighofer CD, Fischer K, Fink A-M, Cramer P, Goede V, Wendtner CM, Hallek M, GCLLSG
No Significant Clinical Benefit of First Line Therapy with Fludarabine (F) in Comparison to Chlorambucil (Clb) in Elderly Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL): Results of a Phase III Study of the German CLL Study Group (GCLLSG)
Blood (ASH Annual Meeting Abstracts) 2007 Nov; 110(11): Abstract #629

Eichhorst BF, Busch R, Obwandner T, Kuhn-Hallek I, Herschbach P, Hallek M; German CLL Study Group.
Health-related quality of life in younger patients with chronic lymphocytic leukemia treated with fludarabine plus cyclophosphamide or fludarabine alone for first-line therapy: a study by the German CLL Study Group
J Clin Oncol. 2007 May 1;25(13):1722-31

Eichhorst BF, Busch R, Schweighofer C, Wendtner CM, Emmerich B, Hallek M; German CLL Study Group (GCLLSG).
Due to low infection rates no routine anti-infective prophylaxis is required in younger patients with chronic lymphocytic leukaemia during fludarabine-based first line therapy
Br J Haematol. 2007 Jan;136(1):63-72

 

2006

Bilban M, Heintel D, Scharl T, Woelfel T, Auer MM, Porpaczy E, Kainz B, Krober A, Carey VJ, Shehata M, Zielinski C, Pickl W, Stilgenbauer S, Gaiger A, Wagner O, Jager U; German CLL Study Group.
Deregulated expression of fat and muscle genes in B-cell chronic lymphocytic leukemia with high lipoprotein lipase expression
Leukemia. 2006 Jun;20(6):1080-8

Moosig F, Schoch R, Kneba M.
Die T-Large Granular Lymphocyte Leukämie (T-LGL-Leukämie): Eine wichtige Differenzialdiagnose zum Felty-Syndrom
Z Rheumatol. 2006; 65(6): 447 - 451

Eichhorst BF, Busch R, Hopfinger G, Pasold R, Hensel M, Steinbrecher C, Siehl S, Jager U, Bergmann M, Stilgenbauer S, Schweighofer C, Wendtner CM, Dohner H, Brittinger G, Emmerich B, Hallek M; German CLL Study Group.
Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia
Blood 2006; 107(3): 885 - 891

 

2005

Bergmann MA, Goebeler ME, Herold M, Emmerich B, Wilhelm M, Ruelfs C, Boening L, Hallek MJ; German CLL Study Group
Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I/II study of the German CLL Study Group
Haematologica. 2005 Oct;90(10):1357-64

Heintel D, Kienle D, Shehata M, Krober A, Kroemer E, Schwarzinger I, Mitteregger D, Le T, Gleiss A, Mannhalter C, Chott A, Schwarzmeier J, Fonatsch C, Gaiger A, Dohner H, Stilgenbauer S, Jager U.
High expression of lipoprotein lipase in poor risk B-cell chronic lymphocytic leukemia
Leukemia  2005; 19: 1216 - 1223

 

2004

Heintel D, Kroemer E, Kienle D, Schwarzinger I, Gleiss A, Schwarzmeier J, Marculescu R, Le T, Mannhalter C, Gaiger A, Stilgenbauer S, Dohner H, Fonatsch C, Jager U; German CLL Study Group.
High expression of activation-induced cytidine deaminase (AID) mRNA is associated with unmutated IGVH gene status and unfavourable cytogenetic aberrations in patients with chronic lymphocytic leukaemia
Leukemia  2004; 18(4): 756 - 62

Dreger P; German CLL Study Group; EBMT.
Transplantation strategies in chronic lymphocytic leukemia: current concepts of the German CLL Study Group and the EBMT
Ann Hematol. 2004; 83 Suppl 1: S68 - 70

Hallek M, Eichhorst BF
Chemotherapy combination treatment regimens with fludarabine in chronic lymphocytic leukemia
Hematol J. 2004; 5 Suppl 1: S20 - 30

Wendtner CM, Ritgen M, Schweighofer CD, Fingerle-Rowson G, Campe H, Jager G, Eichhorst B, Busch R, Diem H, Engert A, Stilgenbauer S, Dohner H, Kneba M, Emmerich B, Hallek M; German CLL Study Group (GCLLSG)
Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission--experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG)
Leukemia. 2004; 18(6): 1093 - 101

Hallek M, Bergmann M, Emmerich B
Chronic lymphocytic leukaemia: up-dated recommendations on diagnosis and treatment
Onkologie. 2004; 27(1): 97 - 104

Dreger P, Stilgenbauer S, Benner A, Ritgen M, Krober A, Kneba M, Schmitz N, Döhner H.
The prognostic impact of autologous stem cell transplantation in patients with chronic lymphocytic leukemia: a risk-matched analysis based on the VH gene mutational status
Blood 2004; 103(7): 2850 - 2858

 

2003

Hallek M, Bergmann M, Goede V, Fingerle-Rowson G, Schweighofer C, Schmitt B, Wendtner CM, Emmerich B
Current concepts in chronic lymphocytic leukemia. Better chances for young patients
MMW Fortschr Med. 2003; 145(27-28): 46-9

 

2002

Schulz H, Klein SK, Rehwald U, Reiser M, Hinke A, Knauf WU, Aulitzky WE, Hensel M, Herold M, Huhn D, Hallek M, Diehl V, Engert A; German CLL Study Group
Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia
Blood. 2002 Nov 1;100(9):3115-20

Schmitt B, Wendtner CM, Bergmann M, Busch R, Franke A, Pasold R, Schlag R, Hopfinger G, Hiddemann W, Emmerich B, Hallek M
Fludarabine combination therapy for the treatment of chronic lymphocytic leukemia
Clin Lymphoma. 2002; 3(1): 26 - 35

Hallek M, Bergmann M, Emmerich B für die Deutsche CLL-Studiengruppe
Chronische lymphatische Leukämie: Aktualisierte Vorschläge zu Diagnostik und Therapie
Dt. Ärzteblatt 2002; Jg.99 (Heft 19): A 1294 - A1301

Stilgenbauer S, Bullinger L, Lichter P and Döhner H. and the German CLL Study Group
Genetics of chronic lymphotic leukemia: genomic aberrations and VH gene mutation status in pathogenesis andclinical course
Leukemia 2002; 16(6): 993 - 1007

 

2001

Huhn D, von Schilling C, Wilhelm M, Ho AD, Hallek M, Kuse R, Knauf W, Riedel U, Hinke A, Srock S, Serke S, Peschel C, Emmerich B; German Chronic Lymphocytic Leukemia Study Group
Rituximab therapy of patients with B-cell chronic lymphocytic leukemia
Blood. 2001 Sep 1;98(5):1326-1331

Hallek M, Schmitt B, Wilhelm M, Busch R, Krober A, Fostitsch HP, Sezer O, Herold M, Knauf W, Wendtner CM, Kuse R, Freund M, Franke A, Schriever F, Nerl C, Dohner H, Thiel E, Hiddemann W, Brittinger G, Emmerich B; German Chronic Lymphocytic Leukaemia Study Group
Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia  (CLL): results of a phase II study of the German CLL Study Group
Br J Haematol. 2001 Aug;114(2):342-348

Hallek M, Buening H, Ried M, Hacker U, Kurzeder C, Wendtner CM
Grundlagen der Gentherapie -Prinzipien und Stand der Entwicklung
Internist 2001; 42(10): 1306 - 1313

 

2000

Döhner H, Stilgenbauer S, Benner A, Leupolt E, Kröber A, Bullinger L, Döhner K, Bentz M, Lichter P
Genomic aberrations and survival in chronic lymphocytic leukemia
N Engl J Med. 2000 Dec 28;343(26):1910-6

von Bubnoff N, Adler S, Danhauser-Riedl S, Kamp T, Nerl C, Emmerich B, Hallek M
The activation of intracellular tyrosine kinases by interferon-alpha (IFNalpha) correlates with its antiproliferative activity in B-lymphoid cell lines, but not in B-cell chronic lymphocytic leukaemia patients
Ann Hematol 2000; 79(3): 119-126

 

1999

Wendtner CM, Schmitt B, Wilhelm M, Dreger P, Montserrat E, Emmerich B, Hallek M
Redefining the therapeutic goals in chronic lymphocytic leukemia: Towards an evidence-based, risk-adapted therapy
Ann Oncol. 1999; 10(5): 505 - 509

Meinhardt G, Wendtner CM, Hallek M
Molecular pathogenesis of chronic lymphocytic leukemia: factors and signaling pathways regulating cell growth and survival
J Mol Med 1999; 77(2): 282 -293

Buhmann R, Nolte A, Westhaus D, Emmerich B, Hallek M
CD40-Activated B-Cell Chronic Lymphocytic Leukemia Cells for Tumor Immunotherapy: Stimulation  of Allogeneic Versus Autologous T Cells Generates Different Types of Effector Cells
Blood 1999; 93(6): 1992 - 2002

Hallek M, Langenmayer I, Nerl C, Knauf WU, Dietzfelbinger H, Adorf D, Ostwald M, Busch R, Kuhn-Hallek I Thiel E, Emmerich B
Elevated serum thymidine kinase levels identify a subgroup at high risk of disease-progressionin early, non-smoldering chronic lymphocytic leukemia.
Blood 1999; 93(5): 1732 - 1737

 

1997

Hallek M, Kuhn-Hallek I, Emmerich B
Prognostic factors in chronic lymphocytic leukemia.
Leukemia 1997; 11 (Suppl.2): S4 - S13

 

1996

Hallek M, Wanders L, Ostwald M, Busch R, Senekowitsch R, Stern S, Schick H-D, Kuhn-Hallek I, Emmerich B
Serum beta(2)-microglobulin and serum thymidine kinase are independent predictors of progressionfree survival in chronic lymphocytic leukemia and immunocytoma.
Leuk Lymphoma 1996; 22(5-6): 439 - 447

Langenmayer I, Knauf W, Nerl C, Dempster S, Hallek M, Adorf D, Dietzfelbinger H, Busch R, Ziegler-Heitbrock HWL, Thiel E, Emmerich B
Interferon-alpha-2b (IFN alpha) for early-phase lymphocytic leukemia with high risk disease-progression: results of a randomized multicenter study.
Br J Haematol. 1996; 94(2): 362 - 369